

Hyalgan®

Hyaluronic acid sodium salt

COMPOSITION

Active ingredient: Hyaluronic acid sodium salt (Hyalectin®) 20 mg

Excipients: Sodium chloride, Monobasic sodium phosphate dihydrate, Dibasic sodium phosphate dodecahydrate, Water for injections q.s. to 2 ml.

SUPPLY

One 2 ml pre-filled syringe for intra-articular use

THERAPEUTIC CATEGORY AND ACTIONS

The intra-articular administration of Hyalgan® into arthritic joints improves joint function, due to the normalization of synovial fluid viscoelasticity and the activation of tissue repair processes in articular cartilage.

MARKETING AUTHORISATION HOLDER AND MANUFACTURER

Fidia Farmaceutici S.p.A.

Via Ponte della Fabbrica, 3/A - 35031 Abano Terme (PD) Italy

INDICATIONS

Traumatic and degenerative joint disease.

Adjuvant in orthopaedic surgery.

CONTRA-INDICATIONS

Individual hypersensitivity to the product. To date, no other contra-indications to the intra-articular administration of hyaluronic acid are known.

WARNINGS AND PRECAUTIONS

It is necessary to follow a correct technique of intra-articular injection in accurately aseptic conditions.

DOSAGE AND ADMINISTRATION

2 ml of HYALGAN® (20 mg) administered intra-articularly once a week for 5 weeks or as directed by the physician.

ADVERSE REACTIONS

HYALGAN® is generally well tolerated. However, in rare cases, some patients have exhibited a transient and moderate pain symptomatology.

In any case, all suspected adverse reactions occurring during the treatment with HYALGAN® should be reported to the physician.

The expiry date reported on the package refers to the product stored correctly in its original package

Warnings: do not use the product after the expiry date reported on the package



fidia
farmaceutici